Peptide quality, purity and third-party testing for UK research contexts
Any research programme working with peptides sourced from third-party suppliers faces a verification problem before it faces a biology problem: does the material in the vial match the label, at the stated purity, free of contaminants that would confound experimental results. This is not a peripheral compliance matter — a mechanistic finding attributed to a peptide that was in fact partially degraded, misidentified, or contaminated is simply not a valid finding, regardless of how carefully the downstream experimental protocol was run.
High-performance liquid chromatography (HPLC) purity is the standard first-line metric, typically reported as a percentage of the total peak area attributable to the target peptide against a reference standard. A reputable certificate of analysis (CoA) reports HPLC purity of 95% or higher for research-grade peptide material, with the chromatogram itself, not just the summary percentage, made available on request. A CoA offering only a bare percentage figure with no accompanying chromatogram is a weaker document than one showing the underlying trace, since the shape and resolution of surrounding minor peaks matters for judging whether the stated purity figure is credible.
HPLC purity alone does not confirm identity — a highly pure sample of the wrong peptide, or of a closely related sequence variant, would still show a clean chromatogram. Mass spectrometry (typically MALDI-TOF or ESI-MS) is the complementary test needed to confirm molecular identity, comparing the observed mass against the expected molecular weight of the target sequence. Reputable suppliers provide both HPLC and MS data as standard, and a CoA offering one without the other should be treated as incomplete rather than sufficient.
Endotoxin testing is a further, frequently overlooked verification step, particularly relevant for any peptide intended for injectable research use. Bacterial endotoxin (lipopolysaccharide) contamination can arise during synthesis or handling and is capable of producing a substantial immune and inflammatory response independent of the peptide's own biological activity, which would confound any experimental readout involving inflammatory markers, cytokine panels or general physiological stress response. The standard test is the Limulus Amebocyte Lysate (LAL) assay, reported in endotoxin units per milligram, with research-grade injectable material typically expected to fall below pharmacopoeial thresholds designed for parenteral use.
Sterility testing and residual-solvent analysis round out a complete CoA for injectable-grade research peptides. Lyophilisation (freeze-drying) processes can leave trace solvents from the synthesis and purification process, and a thorough supplier will report these alongside the core purity, identity and endotoxin data rather than treating them as unnecessary detail for a research-only product.
Batch-to-batch consistency is a separate concern from any single CoA's contents. A research programme running a multi-week or multi-month protocol should request CoAs specific to the batch or lot number actually supplied, not a generic or historical CoA for the product line generally, since peptide synthesis batches can vary meaningfully in purity even from the same manufacturer using the same nominal process.
Third-party verification — independent laboratory testing commissioned by the purchaser or by an intermediary with no financial stake in the supplier's sales — is the more rigorous standard where budget and protocol importance justify it. Supplier-issued CoAs, however complete, carry an inherent conflict of interest, and for any finding intended for publication or serious internal research use, independent confirmation of at least identity and purity on a sample basis is the more defensible practice.
Storage and handling documentation is the final practical layer connecting quality at receipt to quality at the point of use. Lyophilised peptides are generally stable for extended periods when stored at -20°C or below and protected from moisture, but stability after reconstitution in solution is typically measured in days to a few weeks even under refrigeration, and this window varies by peptide. A supplier's CoA is only as useful as the storage and handling practice applied after the material arrives.
The research implication is that quality verification should be budgeted and planned as a distinct line item in any peptide research protocol, not assumed as a background guarantee. A mechanistically interesting result built on unverified material is not a result that can be defended, replicated, or usefully compared against other groups' findings using nominally the same compound.